Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.7K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.7K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.7K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.7K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gestational Dynamics of Hofbauer Cells in the Human Placenta: Distribution, Morphology, and Immunophenotype.

Journal of developmental biology·2026
Same author

Metabolically Induced Intestinal Inflammation: The Role of ER Stress and Autophagy in a Porcine Model of Diabetes.

Research square·2026
Same author

Glucagon-like peptide 1 receptor agonists: anti-inflammatory effects in cardiovascular diseases.

Canadian journal of physiology and pharmacology·2026
Same author

Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina.

Technology and health care : official journal of the European Society for Engineering and Medicine·2026
Same author

Ursodeoxycholic Acid Attenuates Lipopolysaccharide-Induced Myocardial Injury by Inhibiting Oxidative Stress, Inflammation, and Apoptosis: The Interplay of Sirt1/Nrf2 and Akt/NF-κB Signaling Pathways.

International journal of molecular sciences·2026
Same author

Balancing public health needs and economic sustainability: A dual-matrix model for community pharmacy inventory management.

Exploratory research in clinical and social pharmacy·2026

Related Experiment Video

Updated: Apr 26, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.1K

Severe hyperkalemia induced by propranolol.

Danijela Mandić, Lana Nezić, Ranko Skrbić

    Medicinski Pregled
    |July 19, 2014
    PubMed
    Summary

    Beta-blocker induced hyperkalemia is a serious complication. Promptly identifying and managing this condition is crucial for patient safety and recovery.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Beta-adrenergic receptor blockade can cause hyperkalemia in 1-5% of patients.
    • Non-cardio-selective beta-blockers increase the risk of developing hyperkalemia.

    Observation:

    • A patient with angina pectoris developed hyperkalemia while on propranolol.
    • Symptoms included weakness, chest tightness, and limb numbness, with lab findings of hyperkalemia (6.6 mmol/L) and ECG changes.

    Findings:

    • Discontinuation of propranolol led to potassium level normalization, ECG improvement, and symptom resolution.
    • The adverse drug reaction probability score confirmed a likely causal link between propranolol and hyperkalemia.

    Implications:

    • Hyperkalemia from non-selective beta-blockers like propranolol can be unpredictable and life-threatening.

    More Related Videos

    Electrocardiogram Recordings in Anesthetized Mice using Lead II
    04:16

    Electrocardiogram Recordings in Anesthetized Mice using Lead II

    Published on: June 20, 2020

    13.5K
    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
    08:32

    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

    Published on: December 18, 2014

    25.3K

    Related Experiment Videos

    Last Updated: Apr 26, 2026

    Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
    08:11

    Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

    Published on: November 11, 2022

    3.1K
    Electrocardiogram Recordings in Anesthetized Mice using Lead II
    04:16

    Electrocardiogram Recordings in Anesthetized Mice using Lead II

    Published on: June 20, 2020

    13.5K
    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
    08:32

    Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

    Published on: December 18, 2014

    25.3K
  • Timely identification of the cause and therapeutic interventions are essential for managing this complication.